



22 June 2022

Termination of Scheme Implementation Deed with Health House International Limited

TERMINATION OF SCHEME

Zelira Therapeutics Limited (ASX:ZLD OTCQB:ZLDAF) and Health House International Ltd (ASX:HHI) (**Health House**) advise that after mutual consultation, they have agreed to terminate the proposed scheme of arrangement (**Scheme**) originally announced to the market on 23 February 2022 given the substantial change in market conditions since the Scheme was originally announced.

As a result of this termination, Health House will make an immediate payment of \$50,000 to Zelira.

In addition, Health House will be required to repay to Zelira the \$1.5 million working capital facility loan, plus interest, within 60 days of this announcement, pursuant to the terms of the Zelira working capital facility loan agreement announced to the market on February 24, 2022.



For further information
please contact

Company

Dr Oludare Odumosu
Managing Director & CEO
☎ +1 909 855 0675
✉ oodumosu@zeliratx.com

Investors

Ronn Bechler
Executive Chairman, Market Eye
☎ +61 400 009 774
✉ ronn.bechler@marketeye.com.au

About Zelira Therapeutics

Australia

Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA
☎ +61 8 6558 0886
Fax: +61 8 6316 3337
✉ enquiries@zeliratx.com
www.zeliratx.com
ACN 103 782 378

USA

5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462
United States Of America
☎ +1 484-630-0650

About Zelira www.zeliratx.com



Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a leading global biopharmaceutical company in the research, development and commercialisation of clinically-validated cannabinoid medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world’s largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE® brand that are generating revenues in Australia, Pennsylvania, Louisiana and Washington D.C. with other states in the US expected to follow. Zelira is also generating revenue in Australia from its proprietary and patented Zenivol® - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol® has successfully completed the first Phase 1b/2a clinical trial for chronic insomnia where it was found to be a safe and effective treatment. This clinical trial is published in the prestigious journal ‘Sleep’. In 2020, Zelira partnered with SprinJene®Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira’s OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company conducts its work in partnership with world-leading researchers and organizations which since inception includes Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent’s Hospital in Melbourne, Australia; and the Children’s Hospital of Philadelphia (CHOP) in the United States.